MAVACAMTEN | MAVACAMTEN | ATC C01EB24
CARDIOVASCULAR CARDIAC MYOSIN INHIBITOR TREATMENT OF NEW YORK HEART ASSOCIATION (NYHA) II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) | ORAL | Tmax 1 HOUR F 85 PERCENT PPB 98 PERCENT HT 180 HOUR SOLUBILITY PRACTICALLY INSOLUBLE IN WATER AT PH 2-10 | CARDIAC MYOSIN | More at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |